Increased Circulating Betatrophin Concentrations in Patients with Type 2 Diabetes

Table 1

Descriptive data and blood sample data for nondiabetic controls and patients with type 2 diabetes. All blood samples were collected after overnight fasting. HbA1c levels are given as NGSP (%) and as IFCC values (mmol/mol) in parenthesis.

Variable	Nondiabetic; (n = 18)	Type 2 diabetes; (n = 27)
Gender	9 male (50%)	17 male (63%)
Age (years)	65.4 ± 1.6	61.9 ± 1.7
Weight (kg)	88.6 ± 5.4	89.7 ± 3.7
BMI (kg/m^2)	29.0 ± 1.3	30.1 ± 1.2
Waist (cm)	101.8 ± 3.8	104.3 ± 3.0
Hip (cm)	108.2 ± 2.9	111 ± 3.2
Waist-hip ratio	0.94 ± 0.02	0.97 ± 0.02
Fasting plasma glucose (mmol/L)	6.2 ± 0.2	8.5 ± 0.4*
HbA1c (% (mmol/mol))	5.8 ± 0.1%; (40.1 ± 0.8)	6.8 ± 0.1%*; (50.6 ± 1.6)
HOMA2%B	108.8 ± 5.95	77.9 ± 8.3*
HOMA2%S	49.1 ± 4.1	48.7 ± 7.3
HOMA2 IR	2.3 ± 0.2	3.1 ± 0.4
Fasting plasma cholesterol (mmol/L)	6.18 ± 0.27	4.55 ± 0.18*
Fasting plasma HDL cholesterol (mmol/L)	1.46 ± 0.09	1.18 ± 0.05*
Fasting plasma LDL cholesterol (mmol/L)	3.98 ± 0.22	2.80 ± 0.15*
Fasting plasma triacylglycerols (mmol/L)	1.54 ± 0.16	1.45 ± 0.12
Plasma creatinine (µmol/L)	75 ± 3	81 ± 3
MDRD-GFR (mL/min)	80.7 ± 3.3	78.4 ± 4.2
Fasting plasma C-peptide (nmol/L)	0.98 ± 0.08	1.20 ± 0.14
Fasting plasma betatrophin (pg/mL)	639 ± 66	893 ± 80*
Lipid-lowering drugs (statins)	n = 4 (22%)	n = 13 (48%)
Hypertensive treatment	n = 5 (28%)	n = 17 (63%)*

∗P < 0.05.